New hope for Tough-to-Treat blood cancer: trial tests Triple-Drug attack
Disease control
Recruiting now
This study is testing whether adding a new oral drug, roginolisib, to two standard drugs (venetoclax and rituximab) is safe and works better for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. About 64 participants will receiv…
Phase: PHASE1, PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Mar 02, 2026 15:27 UTC